|

Amplitude Titration to Improve ECT Clinical Outcomes

RECRUITINGN/ASponsored by University of New Mexico
Actively Recruiting
PhaseN/A
SponsorUniversity of New Mexico
Started2023-09-14
Est. completion2027-01-01
Eligibility
Age50 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05699226

Summary

A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of major depressive disorder or bipolar II
* Clinical indications for ECT with right unilateral electrode placement

Exclusion Criteria:

* Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
* Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)
* Current drug or alcohol use disorder (except for nicotine)
* Contraindications to MRI.

Conditions3

Cognitive ChangeDepressionECT

Locations1 site

University of New Mexico Health Science Center
Albuquerque, New Mexico, 87110
Chris Abbott, MD505-272-2223cabbott@salud.unm.edu

Browse More Trials

Depression trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.